In the press

Matthew Read comments on SSIT’s new investment in Investment Week

Biotech trusts top performance charts in February

Matthew Read comments on SSIT’s further investment in Skylo in Robin Amos’ article:

“Ultimately, Skylo will still need to translate its technological promise into sustained commercial success, but the investment also illustrates how the C share fundraising has given SSIT the firepower to stand its corner during fundraisings for promising holdings rather than risk dilution as they raise further capital.”

Read the article here